D9Z Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthMulti-year revenue expansion indicates sustained patient demand and broader clinic activity. Continued positive TTM growth supports the view that the operating network can keep increasing its scale over the medium term.
Strong Profitability And Cash GenerationConsistently strong margins and operating cash flow above accounting earnings indicate good earnings quality. Positive and improving free cash flow gives the business internal funding capacity for clinic investment and operations.
Material DeleveragingA substantially lower debt burden improves financial flexibility and reduces exposure to financing stress. Combined with rising equity and assets, the stronger balance sheet should support resilience and continued investment.
Bears Say
Margin VolatilityRecent margin changes suggest exposure to procedure mix, pricing, staffing, or other cost pressures. If volatility persists, revenue growth may translate less reliably into operating profit and cash generation.
Moderate Free-Cash-Flow ConversionAlthough cash generation is positive, only moderate conversion of earnings into free cash flow indicates ongoing reinvestment needs or working-capital swings. This can constrain funds available for expansion, dividends, or debt reduction.
Elective, Out-of-Pocket DemandReliance on patient-funded elective procedures makes demand more sensitive to household affordability and willingness to spend. This structural exposure can affect procedure volumes and pricing power during weaker consumer conditions.
Clinica Baviera News
D9Z FAQ
What was Clinica Baviera, SA’s price range in the past 12 months?
Currently, no data Available
What is Clinica Baviera, SA’s market cap?
Clinica Baviera, SA’s market cap is CHF902.15M.
When is Clinica Baviera, SA’s upcoming earnings report date?
Clinica Baviera, SA’s upcoming earnings report date is Nov 05, 2026 which is in 59 days.
How were Clinica Baviera, SA’s earnings last quarter?
Clinica Baviera, SA released its earnings results on Jul 29, 2026. The company reported $0.703 earnings per share for the quarter.
Is Clinica Baviera, SA overvalued?
According to Wall Street analysts Clinica Baviera, SA’s price is currently Undervalued.
Does Clinica Baviera, SA pay dividends?
Clinica Baviera, SA does not currently pay dividends.
What is Clinica Baviera, SA’s EPS estimate?
Clinica Baviera, SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clinica Baviera, SA have?
Clinica Baviera, SA has 16,307,580 shares outstanding.
What happened to Clinica Baviera, SA’s price movement after its last earnings report?
Clinica Baviera, SA reported an EPS of $0.703 in its last earnings report. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Clinica Baviera, SA?
Currently, no hedge funds are holding shares in CH:D9Z
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clinica Baviera, SA
Clínica Baviera, S.A., a healthcare provider, manages a substantial chain of ophthalmological centers. This organization dedicates itself to the comprehensive diagnosis, therapeutic intervention, and continuous monitoring of diverse ocular conditions. Its facilities offer a wide range of specialized services, addressing issues such as myopia, hyperopia, astigmatism, presbyopia, cataracts, retinal disorders, pediatric eye ailments, glaucoma, strabismus (squint), corneal diseases, neuro-ophthalmology, lacrimal duct problems (vías lagrimales), and oculoplastic procedures. Operating around 90 sites, the company's geographical footprint extends across Spain, Germany, Austria, and Italy. The corporate headquarters are located in Madrid, Spain.
D9Z Stock 12 Month Forecast
Average Price Target
$67.29